Sitagliptin Phosphate CAS 654671-78-0

Sitagliptin Phosphate CAS 654671-78-0

CAS NO: 654671-78-0
Molecular Formula: C16H18F6N5O5P
Molecular Weight: 505.31
EINECS NO: 1806241-263-5
MDL NO: MFCD22628883
Chat Now

Product Details

Product Description

Product Name: Sitagliptin Phosphate CAS NO:654671-78-0

 

 

Synonyms:

(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone phosphate (1:1);

1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)-, phosphate (1:1);

(3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one phosphate (1:1);

 

 

Chemical & Physical Properties

Appearance : white solid

Assay :≥99.0%

Boiling Point:529.9℃

Flash Point:274.3℃

Melting Point: 202-204℃

 

 

Sitagliptin phosphate is dipeptidyl peptidase Ⅳ(DDP-4) inhibitor class of drugs developed by the German Merck company and firstly obtained the US Food and Drug Administration approval for the treatment of type 2 diabetes, is a new antidiabetic drug, can improve the body's own ability to reduce high blood glucose levels, and the relatively increase naturally occurring incretin by inhibiting the activity of this enzyme, including the levels of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide, thereby triggering the pancreas to improve insulin production and stop glucose production in liver, and ultimately reduce the clinical effect of blood glucose concentration. Features of this product is to stimulate insulin secretion, at the same time can alleviate hunger, but does not make weight gain, and also cannot happen hypoglycemia and edema, is not suitable for use in diabetic patients with poor glycemic control and often developed hypoglycemia. By verification of clinical 552 cases of mild to moderate type 2 diabetes, taken once a day Sitagliptin phosphate, once time 100 mg, after taking the drug for 12 weeks, can make glycated hemoglobin reduce 0.6%-1.1%. Incidence of adverse reactions is similar to placebo, the most frequently reported adverse reactions (incidence> 5% and greater than placebo) is a stuffy or runny nose, and sore throat, upper respiratory tract infection and headache.

Clinical studies showed that the Sitagliptin phosphate as monotherapy in patients with type 2 diabetes, can make glycated hemoglobin (HbA1c) levels significantly reduce. When in combination with the metformin or TZDs, has a significant role of adjuvant therapy, can focus on three kinds of major defect in type 2 diabetes: insulin resistance, β-cell dysfunction (reduction of insulin release), and α-cell dysfunction (unsuppressed hepatic glucose generation) plays a role. But the drug should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

 


Hot Tags: sitagliptin phosphate cas 654671-78-0, manufacturers, suppliers, factory, buy, in stock, 2,3,5-Trimethyl Hydroquinone, 1-(3-Ethyl-4-hydroxymethyl-phenyl)ethanone, CAS 77095-51-3, CAS NO:155213-67-5, 2-Bromo-6-Nitroanisole, Fine Chemicals

Inquiry

You Might Also Like